Skip to main content
. 2021 Dec 17;13(1):4. doi: 10.1038/s41419-021-04174-w

Fig. 6. Blockade of OLR1/c-MYC/SULT2B1 axis reduces glycolytic metabolism to restrain proliferation and chemoresistance of colon cancer cells.

Fig. 6

Colon cancer cells were transfected with sh-NC + oe-NC, sh-OLR1 + oe-NC, or sh-OLR1 + oe-SULT2B1. A The mRNA expression of OLR1, c-MYC, and SULT2B1 in colon cancer cells checked by RT-qPCR. B ECAR of colon cancer cells. C Glucose content in colon cancer cells. D Lactate production in colon cancer cells. E The ATP/ADP in colon cancer cells. F RT-qPCR to detect the mRNA expression of GLUT1 and LDHA in colon cancer cells. G The proliferation level of colon cancer cells estimated using MTS. H Detection of colon cancer cell clone formation. I The mRNA expression of Ki67 detected by RT-qPCR. Colon cancer cells were transfected with sh-NC + oe-NC, sh-OLR1 + oe-NC, or sh-OLR1 + oe-SULT2B1, followed by treatment with DDP, oxaliplatin, 5-Fu, and paclitaxel. J The drug resistance of colon cancer cells to DDP, oxaliplatin, 5-Fu, and paclitaxel assessed by MTS. K The expression of P-gp and SMAD4 in colon cancer cells tested by RT-qPCR. The cell experiment was repeated three times. *p < 0.05 between two groups.